EpiVario Inc. is pioneering epigenetic therapeutic development to redefine treatment landscapes for neuropsychiatric disorders. Spun out of the Epigenetics Institute at the University of Pennsylvania, the company develops innovative therapeutics targeting a newly identified epigenetic process involved in trauma-induced fear and stress responses, and addiction-related drug craving. This discovery provides a unique therapeutic target for addressing obstinate neuropsychiatric disorders such as PTSD and substance use disorders. Leveraging their paradigm-shifting finding, EpiVario’s leading program spearheads the field with a pharmacotherapeutic designed explicitly for smoking cessation. The company has already successfully showcased the efficacy of a small molecule inhibitor in curbing drug-seeking behavior, evidenced by a translative rat-nicotine model.